The effects of lowering uric acid levels using allopurinol on markers of metabolic syndrome in end-stage renal disease patients: A pilot study

Anadolu Kardiyoloji Dergisi

Volumn 9, Issue 5, 2009, Pages 385-389

  Shelmadine, Brian ^a   Bowden, Rodney G ^a   Wilson, Ronald L ^b   Beavers, Daniel ^a   Hartman, Jessica ^a  

^a BAYLOR UNIVERSITY   (United States)

^b Central Texas Nephrology Associates   (United States)

Author keywords

Allopurinol; End stage renal disease; Hyperuricemia; Metabolic syndrome

Indexed keywords

ALLOPURINOL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; URIC ACID; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE MARKER; FEMALE; GOUT; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MALE; METABOLIC SYNDROME X; OPEN STUDY; PILOT STUDY; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL;

ADULT; ALLOPURINOL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; FEMALE; GOUT SUPPRESSANTS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PILOT PROJECTS; RENAL DIALYSIS; TRIGLYCERIDES; URIC ACID;

EID: 70849105887     PISSN: 13028723     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Kaysen G. Metabolic syndrome and renal failure: similarities and differences. Panminerva Med 2006; 48: 151-164
2. Chen LY, Zhu WH, Chen ZW, Dai HL, Ren JJ, Chen JH, et al. Relationship between hyperuricemia and metabolic syndrome. J Zhejiang Univ Sci B 2007; 8: 593-598
3. National Institutes of Health. Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults- Third Report. Washington, DC: U.S. Government Printing Office. 2002.
4. Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med 2007; 120: 442-447 (Pubitemid 46656248)
5. Lin J, Chiou W, Chang H, Liu F, Weng H. Serum uric acid and leptin levels in metabolic syndrome: a quandary over the role of uric acid. Metabolism 2007; 56: 751-756 (Pubitemid 46734081)
6. Emmerson B. Hyperlipidaemia in hyperuricemia and gout. Ann Rheum Dis 1998; 58: 509-510
7. Becker M, Meenakshi J. Hyperuricemia and associated diseases. Rheum Dis Clin N Am 2006; 32: 275-293
8. Nakagawa T, Hu H, Zharikov S, Tuttle KR, Short RA, Glushakova O, et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 2006; 290: F625-31. (Pubitemid 43724964)
9. Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int 2005; 67: 1739-1742
10. Nakagawa T, Tuttle KR, Short RA, Johnson RJ. Hypothesis: fructose-induced hyperuricemia as a causal mechanism for the epidemic of the metabolic syndrome. Nat Clin Pract Nephrol. 2005; 1: 80-86
11. Cardillo C, Kilcoyne CM, Cannon RO, Quyyumi AA, Panza JA. Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients. Hypertension 1997; 30: 57-63. (Pubitemid 27306347)
12. Butler R, Morris AD, Belch JJ, Hill A, Struthers AD. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension 2000; 35: 746-751 (Pubitemid 30165320)
13. Struthers AD, Donnan PT, Lindsay P, McNaughton D, Broomhall J, MacDonald TM. Effect of allopurinol on mortality and hospitalizations in chronic heart failure: a retrospective cohort study. Heart 2002; 87: 229-234 (Pubitemid 34177675)
14. Kanbay M, Özkara A, Selcoki Y, Işik B, Turgut F, Bavbek N, et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearance, and proteinuria in patients with normal renal functions. Int Urol and Nephrol 2007; 39: 1227-1233 (Pubitemid 350193621)
15. Gibson T, Grahame R. Gout and hyperlipidemia. Ann Rheum Dis 1974; 33: 298-303.
16. Ulreich A, Kostner GM, Pfeiffer KP, Sedlmayr P, Rainer F. Serum lipids and lipoproteins in patients with primary gout. Rheumatol Int. 1985; 5: 73-77 (Pubitemid 15167146)
17. Suliman, ME, Johnson, RJ, Garcia-Lopez, E, Qureshi, AR, Molinaei, H, Carrero JJ, et al. J-shaped mortality relationship for uric acid in CKD. Amer J Kid Dis 2006; 48: 761-771 (Pubitemid 44740052)
18. Minami M, Ishiyama A, Takagi M, Omata M, Atarashi K. Effects of allopurinol, a xanthine oxidase inhibitor, on renal injury in hypercholesterolemia- induced hypertensive rats. Blood Press 2005; 14: 120-125 (Pubitemid 40645499)
19. Bendersky G. Etiology of hyperuricemia. Ann Clin Lab Sci 1975; 5: 456-467
20. Bowden RG, Hebert S, Wilson R, Gentile M, Lanning B. Comparison of lipid measures and risk stratification among End-Stage Renal Disease patients. J Nephrol 2007; 21: 212-218 (Pubitemid 47072405)
21. Osgood D, Corella D, Demissie S, Cupples LA, Wilson, PW, Meigs JB, et al. Genetic variation at the scavenger receptor class B type I gene locus determines plasma lipoprotein concentrations and particle size and interacts with type 2 diabetes: the Framingham study. J Clin Endocrinol Metab 2003; 88: 2869-2879 (Pubitemid 36724469)
22. Tsutsumi Z, Yamamoto T, Moriwaki Y, Takahashi S, Hada, T. Decreased activities of lipoprotein lipase and hepatic triglyceride lipase in patients with gout. Metabolism 2001; 50: 52-954. (Pubitemid 32761662)
23. Bluestone R, Lewis B, Mervart I. Hyperlipoproteinaemia in gout. Ann Rheum Dis 1971; 30: 134-137
24. Darlington LG, Scott JT. Study of the effect of hypouricaemic therapy on serum lipid levels in gout patients. Adv Exp Med Biol 1986; 195 Pt A:341-344